WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda
- 31 May 2007
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (9) , 1208-1210
- https://doi.org/10.1097/qad.0b013e32810c8dce
Abstract
The ability of WHO clinical staging to predict CD4 cell counts of 200 cells/microl or less was evaluated among 1221 patients screened for antiretroviral therapy (ART). Sensitivity was 51% and specificity was 88%. The positive predictive value was 64% and the negative predictive value was 81%. Clinical criteria missed half the patients with CD4 cell counts of 200 cells/microl or less, highlighting the importance of CD4 cell measurements for the scale-up of ART provision in resource-limited settings.Keywords
This publication has 3 references indexed in Scilit:
- The Added Value of a CD4 Count to Identify Patients Eligible for Highly Active Antiretroviral Therapy Among HIV-Positive Adults in CambodiaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- When to Begin Highly Active Antiretroviral Therapy? Evidence Supporting Initiation of Therapy at CD4+ Lymphocyte Counts <350 cells/ LClinical Infectious Diseases, 2003
- Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studiesThe Lancet, 2002